WO1993024631A1 - PRODUCTION DE STREPTAVIDINE A PARTIR DU $i(BACILLUS SUBTILIS) - Google Patents

PRODUCTION DE STREPTAVIDINE A PARTIR DU $i(BACILLUS SUBTILIS) Download PDF

Info

Publication number
WO1993024631A1
WO1993024631A1 PCT/US1993/005240 US9305240W WO9324631A1 WO 1993024631 A1 WO1993024631 A1 WO 1993024631A1 US 9305240 W US9305240 W US 9305240W WO 9324631 A1 WO9324631 A1 WO 9324631A1
Authority
WO
WIPO (PCT)
Prior art keywords
streptavidin
fused
protein
sequence encoding
signal peptide
Prior art date
Application number
PCT/US1993/005240
Other languages
English (en)
Inventor
Vasantha Nagarajan
Original Assignee
E.I. Du Pont De Nemours And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by E.I. Du Pont De Nemours And Company filed Critical E.I. Du Pont De Nemours And Company
Priority to EP93914323A priority Critical patent/EP0644938A1/fr
Priority to JP6500855A priority patent/JPH07507449A/ja
Publication of WO1993024631A1 publication Critical patent/WO1993024631A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag

Definitions

  • This invention relates to a method for cloning the streptavidin gene into B. subtilis and the secretion of tetrameric, biologically active streptavidin protein into the growth medium.
  • Streptavidin is a tetrameric protein isolated from the actinobacterium Streptomyces avidinii and is remarkable for its ability to bind up to four molecules of d-biotin with unusually high affinity (1).
  • Streptavidin is a nearly neutral 60,000 dalton protein consisting of four identical subunits each having a molecular weight of 15,000 daltons (2).
  • the ability of streptavidin to bind derivitized forms of biotin has led to its widespread use in diagnostic assays where high affinity protein-ligand interactions are important.
  • streptavidin coated liposomes used for drug delivery and diagnostic tests to detect human antibodies or pathogens using streptavidin linked to enzymes such as alkaline or phosphatase or horseradish peroxidase. Streptavidin is currently produced in commercial quantities by
  • Argarana and Meade (2) and (3) describe the cloning of the streptavidin gene from a genomic library of
  • Streptomyces avidinii as well as the DNA sequence of the coding region of the gene.
  • Meade also reports secretion of 250 mg/liter of streptavidin from S. llvidans. This process is time-consuming as the fermentation time alone is 4 to 7 days.
  • Cantor (4) describes the isolation of the DNA which encodes streptavidin from Streptomyces avidniii, which includes the region encoding the signal peptide and the subsequent cloning of the DNA into a bacterial host cell, typically E. coli . Additionally, Cantor describes the construction and subsequent expression in bacteria of a fused gene comprising a first DNA fragment encoding a target protein of interest (specifically human LDL receptor) fused to a DNA fragment encoding streptavidin.
  • a target protein of interest specifically human LDL receptor
  • Sano and Cantor (5) describe the construction of systems for expressing the cloned streptavidin gene in E. coli where the streptavidin accumulated to more than 35% of the total cell protein.
  • Sano further describes the creation of expression vectors for streptavidin containing chimeric proteins which are also capable of expression in E. coli (6). Meade shows that
  • streptavidin is present in the periplasm of E. coli .
  • the work of Sano and Cantor has indicated that the streptavidin signal peptide does not function in E. coli .
  • B. subtilis a gram positive bacterium, has great potential for producing commercially important proteins because it can be genetically manipulated, adapted to various nutritional and physical conditions of growth, and because it is not pathogenic or toxigenic to humans. Under the proper conditions, B. subtilis is known to synthesize and secrete specific proteins relatively free of contaminating species making the proteins easier to purify.
  • prorennin insulin
  • human growth hormone interferon and urokinase
  • Vectors enabling the secretion of a number of different heterologous proteins by B. subtilis have been demonstrated (8), (9), and (10). These include vectors that are based on genes for bacterial exoenzymes such as amylase, protease, levansucrase and ⁇ -lactamases.
  • amyloliquefaciens They found that only a low amount of interferon was secreted.
  • Nagarajan describes a method to design vectors for the secretion of heterologous proteins in bacteria, including B. subtilis.
  • the method is drawn to ways of enabling combinations of promoters, ribosome binding sequences and signal peptides with sequences from desired heterologous proteins such that translocation via an effective signal peptide is achieved.
  • streptavidin secretion by B. subtilis the method disclosed will not ensure a commercially viable secretion process. It is known, for example, that the tetrameric form of streptavidin protein is needed for efficient biotin binding and prior to the instant invention it had not been demonstrated that
  • B. subtilis could efficiently secrete and accumulate a tetrameric protein. Most of the proteins that have been efficiently secreted to date are monomeric proteins, with the exception of E. coli alkaline phosphatase which is dimeric. Also, the production of biologically active streptavidin in the B. subtilis growth medium requires several processes to occur simultaneously and
  • oligomerization in B. subtilis occurs in the space between the cell membrane and cell wall, or if it occurs in the growth medium. Further, it is known that the Streptomyces genome contains a high GC base pair content of at least 70%, whereas the GC content in B. subtilis is known to be on the order of 42%. This would indicate that translation of a Streptomyces gene by B. subtilis may not be possible due to ca incongruous number of GC codons in the Streptomyces genes. Furthermore, it is well known that B. subtilis secretes some proteins very inefficiently, which, in the case of streptavidin, would prove lethal to the cell.
  • the instant invention provides a method for efficiently expressing and secreting soluble, active streptavidin from
  • This invention provides a method for producing tetrameric, biologically active streptavidin by
  • exproteins of bacteria and said expression element is isolated from DNA encoding gram positive bacterial proteins
  • This invention further provides a Bacillus subtilis bacterium transformed as described in (a) above.
  • This invention also provides a method for producing a fused gene product comprised of tetrameric
  • transforming Bacillus subtilis with a fused gene construct comprising a sequence encoding the streptavidin gene fused to a sequence encoding a second desired protein wherein said fused sequence is operably linked to a sequence encoding a signal peptide and an expression element; wherein said sequence encoding a signal peptide is isolated from DNA encoding exoproteins of bacteria and said expression element is isolated from
  • This invention further provides a Bacillus subtilis bacterium transformed with the fused gene construct as described in (a) above, and also the fused gene products as described above.
  • plasmids pBE659, pBE660, pBE661, pBE662, pBE663, pBE673 and pBE655 are provided.
  • Figure la describes the construction of a plasmid pBE659 containing a hybrid gene fusion construct
  • pBE651 The DNA sequence across npr signal peptide cleavage site in pBE83 is designated as SEQ ID NO: 10.
  • SEQ ID NO: 11 The DNA sequence across sav mature protein sequence in pBE651 is designated as SEQ ID NO: 11.
  • Figure lb describes the DNA sequence of the streptavidin gene.
  • the DNA sequence is designated as SEQ ID NO:13.
  • the amino acid sequence is designated as SEQ ID NO:14.
  • Figure 2 describes the construction of plasmids containing the gene fusion constructs pBE660 (apr-sav), pBE661 (npr-sav), pBE662 (bar-sav), and pBE663 (Ivs-sav) from the plasmids pBE30 (apr-phoA), pBE90 (npr-phoA), pBE91 (bar-phoA), and pBE597 (lvs-phoA), respectively.
  • Figure 3 is a Western Blot analysis of B. subtilis, pBE20, and pBE659 culture supernatant, respectively.
  • Figure 4a depicts the U.V. absorption spectra of fractions eluted from an,iminobiotin agarose column loaded with an ammonium sulfate fraction of B. subtilis growth media.
  • Figure 4b depicts the U.V. absorption spectra of fraction eluted from a Sephacryl S200 column loaded with the streptavidin-containing fraction from the
  • Figure 4c is a Western Blot analysis of fractions from both the iminobiotin and S200 columns.
  • Figure 5a describes the creation of plasmid pBE93 (npr-phoA) from plasmid pBE592 (lvs-phoA) by
  • Figure 5b depicts a Western blot of B. subtilus strains containing pBE659 (1-159) and pBE673 (15-159).
  • FIG. 6 describes the streptavidin-heterologous gene (PhoA) fusions: Npr ss -Sav 15-133 -PhoA;
  • Figure 7 describes the EcoRV digestion and ligation of the lvs expression element and mature lvs gene from plasmid pBE311 with the mature sav gene of pBE653 (sav) to produce the plasmid pBE655 containing the gene fusion lvs-sav-lvs.
  • Meture protein is the final protein product without the signal peptide attached.
  • “Desired protein” is any protein considered a valuable product to be obtained from genetically
  • second desired protein is used herein to describe that protein which, in the fused gene product of the
  • the fused gene construct may be constructed so that the streptavidin is fused to either the C-terminus, or the N-terminus, of the second desired protein.
  • Signal peptide is an amino terminal p ⁇ lypeptide preceding the secreted mature protein.
  • the signal peptide is cleaved from and is therefore not present in the mature protein.
  • Signal peptides function by directing and translocating extracellular proteins across cell membranes.
  • Signal peptide is also referred to as signal protein.
  • “Compatible restriction sites” are different restriction sites which, when cleaved, yield nucleotide ends that can be ligated without any additional
  • apr and “Apr” refer to alkaline protease gene and protein, respectively.
  • Bar and Bar refer to ribonuclease gene and protein, respectively.
  • Lvs and “Lvs” refer to levansucrase gene and protein, respectively.
  • npr and Npr refer to neutral protease gene and protein, respectively.
  • phoA and PhoA refer to E. coli alkaline phosphatase gene and protein, respectively.
  • sav and “Sav” refer to streptavidin gene and protein, respectively.
  • streptavidin refers to the protein comprising amino acid residues 1-159 of a 2 kb BamHI fragment isolated from spreptomyces avidinii as
  • biotin refers to biotin, biotin
  • biotin analogs capable of binding streptavidin.
  • Am- refers to ampicillin.
  • Kan- refers to kanamycin.
  • Cm- refers to chloramphenicol.
  • “Shuttle phagemid” as used herein is a vector that is normally double stranded and contains both the origins of replication for E. coli and B. subtilis and also the F1 intragenic region for the preparation of single stranded DNA.
  • expression element refers herein to a
  • B. subtilis including, for example, the promoter sequence and the ribosome binding site sequence.
  • exoproteins of bacteria is used to describe those proteins produced by bacteria which are able to cross the cytoplasmic bacterial membrane and are known to be naturally secreted into the bacterial growth media.
  • gram positive bacterial proteins refers to those proteins which are known to be naturally synthesized by gram positive bacteria.
  • biologically active refers to a soluble streptavidin protein molecule which is able to bind to biotin, biotin analogs, or
  • the source of the bacteria strains, genes and the various vectors described herein are readily available to one skilled in the art.
  • the complete nucleotide sequence for the genes for apr, npr, bar and lvs from B . amyloliquefaciens, the E. coli phoA gene and the sav gene from S. avidinii have been published (2), (19), (20), (21), and (22).
  • these sequences are accessible in the GenBank from Nucleic Acid Data base from Los Almos, California.
  • the bacterial strains B. subtilis, E. coli and S. avidinii and plasmids pBE322, pTZ18R, pSK, pC194, pUB110 and phage M13KO7 are readily available from a variety of sources. For example, they can be obtained from the American Type Culture Collection, Rockville, MD, or the Bacillus Stock Center, Ohio, and are also available from other commercial suppliers.
  • the position of the newly engineered restriction sites and sequence of the mutagenic oligonucleotide is indicated in the figures or examples and one skilled in the art may readily prepare these constructs with the available information in this art.
  • the anti-streptavidin antiserum can be purchased from several manufacturers. In the present study, it was purchased from Sigma, St. Louis, MO. The
  • streptavidin used as standard was obtained from Bethesda
  • the present invention utilizes an isolated 2 kb DNA fragment which encodes streptavidin ( Figure lb).
  • the DNA was isolated according to techniques well known in the art based on published DNA sequence (2, 3). The
  • 2 kb fragment contains the entire sav open reading frame encoding a signal peptide and the mature protein which comprises amino acid sequences 1-159 and the flanking region DNA which occurs naturally at the 3' and 5' ends of the coding region.
  • a recombinant cloning vehicle which comprises DNA encoding a suitable expression element for streptavidin expression and the DNA fragment encoding the streptavidin protein, wherein said cloning vehicle is further characterized by the presence of a first and a second restriction enzyme site, the DNA fragment encoding streptavidin being inserted into said site.
  • the present invention entails development of a vector which comprises expression elements including a promoter sequence controlling transcription and a ribosomal binding site sequence controlling translation; and also a sequence for a signal peptide which enables translocation of the protein through the bacterial membrane and the cleavage of the signal peptide from the mature protein.
  • Suitable vectors will be those which are compatible with the bacterium employed. For example, for B. subtilis such suitable vectors include
  • E. coli-B subtilis shuttle vectors which have compatible regulatory sequences and origins of replication. They will be preferably multicopy and have a selective marker gene, for example, a gene coding for antibiotic
  • pTZ18R is a phagemid
  • the expression elements containing DNA sequences encoding the promoter and ribosome binding site may be from any gram positive bacterial protein, and the signal peptide may be from any single bacterial gene which encodes a secreted product.
  • the DNA sequences encoding the promoter and ribosome binding site may also be from a different gene than that encoding the signal peptide.
  • These DNA sequences encoding the promoter, ribosome binding site and signal peptide can be isolated by means well known to those skilled in the art and illustrative examples are documented in the literature (23).
  • the promoters in the DNA sequences may be either
  • Suitable signal peptides and expression elements may be selected from the group comprising, for example, apr, npr, lvs and bar.
  • restriction endonuclease cleavage site to the 3' end of the DNA encoding the signal peptide is also easily accomplished by means well known to those skilled in the art (16).
  • Several methods may be employed to add the restriction endonuclease cleavage site to the 3' end of the DNA encoding the signal peptide.
  • One such method might incorporate polymerse chain reaction (PCR).
  • PCR polymerse chain reaction
  • the method used in the present invention is site-directed mutagenesis which is most preferred, and is described in Mutagene manual (Biorad,
  • restriction endonuclease site on the 3' end of the DNA sequence encoding the signal peptide and that on the 5' end of the DNA sequence encoding the mature desired protein must be compatible. Suitable compatible restriction sites are well known in the art. See, for example the Restriction Fragment Compatibility Table of the New England Biolabs 1988-1989 Catalog, New England Biolabs, Inc., Beverly, MA 01915 (1988), which is herein incorporated by reference. Preferred for use herein are EcoRV or NheI.
  • compatible restriction site at its 5' end can be operably integrated by conventional techniques (16) and (17).
  • the recombinant cloning vehicle of the present invention has been inserted into a bacterial host cell.
  • a suitable host cell would be derived from the genus Bacillus, the most preferred host cell would be of the species subtilis.
  • One method to transform B. subtilis bacteria is described by Vasantha et al. (9). Standard microbiological methods well known to those skilled in the art can be used for the growth and maintenance of bacterial cultures.
  • subtilis host cells containing the recombinant cloning vehicle of the present invention have been prepared by transforming the strain BE1500 or its derivatives (1510) with the plasmids, pBE659A, pBE660, pBE661, pBE662, pBE663, pBE673, pBE659 and pBE655.
  • BE1500 has the genotype trpC2, metB10, lys3, ⁇ -aprE66, ⁇ -npr82, ⁇ -sacB::ermC (24).
  • a method of producing streptavidin comprises cultivating a genetically engineered host cell of the present invention under suitable conditions permitting expression of the streptavidin gene and recovering the streptavidin so produced from the growth media.
  • the present invention also provides a fused gene which comprises a first DNA fragment encoding
  • streptavidin fused to a second DNA fragment encoding a target protein of interest and wherein the fused gene is capable of expressing a fused protein in vivo when the gene is inserted into a host cell.
  • the second DNA fragment is the gene encoding B. amyloliquefaciens levansucrase (Lvs).
  • a fused gene expresses a protein which consists of streptavidin at the N-terminal region of the fused protein and levansucrase at the C-terminal region of the fused protein when the fused gene is inserted into a suitable expression vector and introduced into a suitable host cell.
  • the fused gene may be cloned into a bacterial expression vector and used to transfect a bacterial host cell with the fused gene.
  • a preferred bacterial host cell is B. subtilis .
  • the invention also provides a secretion vector capable of expressing and secreting the fused gene of the present invention when said vector is introduced into a suitable host cell.
  • the vector comprises DNA encoding the promoter, ribosomal binding site and signal sequence of the first gene followed by DNA encoding the mature protein of the first gene, fused to DNA encoding the mature protein of the second gene.
  • a fused protein encoded by the fused gene of the present invention wherein a desired protein of interest is fused to streptavidin.
  • the desired protein is B. amyloliquefaciens levansucrase.
  • bacteria secreting streptavidin are grown in a standard growth media such as S7 medium and are
  • the proteins in the growth media may be concentrated either by membrane filtration techniques or ammonium sulfate precipitation or both, but most preferably by 70% ammonium sulfate precipitation.
  • the concentrated proteins are reconstituted in an appropriate. buffer compatible with binding to an iminobiotin affinity resin.
  • the buffer for the reconstitution of the protein and the equilibration of the iminobiotin affinity resin is preferably about pH 8.5 to pH 11.0, but most
  • the concentrated protein fraction is loaded onto the iminobiotin affinity resin where the streptavidin is bound.
  • the column is washed with equilibration buffer and the streptavidin is eluted with an ammonium acetate buffer, most preferably 50mM ammonium acetate at about pH 4.0.
  • fractions are identified by U.V. detection and are further desalted and purified by standard gel filtration chromatography. Several gel filtration resins may be used but Sephacryl 200 is preferred. Final
  • determination of the presence of pure streptavidin may be made by several methods, including for example.
  • the examples illustraterate the isolation of the streptavidin gene, and the engineering of suitable closing vectors containing ligated DNA encoding operable expression elements and streptavidin.
  • the examples also describe the transformation of Bacillus host cells capable of expressing and secreting the streptavidin protein and the means whereby said streptavidin may be purified.
  • the sav gene was isolated as a 2 kb BamHI fragment by standard methods from Streptomyces avidinii and cloned in plasmid pSK (Stratagene, 11099 North Torrey Pines Road, La Jolla, CA 92037).
  • An EcoRV site was engineered at the start site of the mature sav gene by site-directed mutagenesis and the resulting plasmid containing the sav gene was designated pBE651.
  • Plasmid pBE83 (24) is an E. coli-B. subtilis phagemid vector containing the npr expression element and signal peptide fused to mature Lvs .
  • B. subtilis strains containing pBE83 secrete Lvs. Colonies can be easily visualized on agar plates due to the formation of levan which is produced in the presence of sucrose contained in the agar.
  • Plasmid pBE83 was digested with EcoRV and BamHI and ligated to the
  • B. subtilis strain BE1510 was transformed with the ligated DNA and plated on LB agar + 5% sucrose + chloramphenicol (5 ug/ml). A total of approximately 800 transformants were obtained and 128 B. subtilis clones that did not produce levansucrase were identified and were screened by colony immunoassay using commercially purchased anti-streptavidin
  • pBE659A Four independent positive clones were obtained and designated as pBE659A, pBE659B, pBE659C and pBE659D. All further characterizations were carried out using plasmid pBE659A, which will be referred to as pBE659. This plasmid has been deposited in the
  • Plasmids pBE30, pBE90, pBE91 and pBE597 all contain the mature sequence of phoA fused to apr, npr, bar and lvs expression elements, respectively. These are shuttle phagemids containing origins of replication, of pBR322, pUB110 and M13K07 (24).
  • PhoA reacts with 5 bromo-4-chloro-3-indolyl phosphate (Sigma, St. Louis, MO) to provide a blue color on the indicator plates
  • Plasmids pBE30, pBE90, pBE91, pBE597 and pBE651 were digested with EcoRV and Pst 1 and separated on 1-2% low melting agarose. The large fragment from pBE30, pBE90, pBE91, ⁇ BE597 and the small fragment from pBE651 were cut and purified using Geneclean (P.O. Box 2284,
  • methylsulfonyl fluoride for 5 min and the supernatant was respun and processed for Western analysis.
  • Samples from pBE659 (npr-sav) vector and commercially purchased streptavidin were separated on a 10 to 20% SDS-PAGE gel (Daiichi min gel, Integrated Separation Systems, MA 01136) followed by protein electroblotting onto a nitrocellulose filter and analyzed using anti-streptavidin antibody (Sigma,
  • B. subtilis can secrete soluble Sav into the growth medium. It was noted that in this instance extracellular streptavidin accumulated to approximately 20 to 30 mg/liter after about 12 hours.
  • plasmid pBE659 was grown in 250 ml of the following medium: 0.6% Casaminoacids in 1X Castenholz medium + 1% glycerol + 0.01% yeast extract + 25 mM potassium phosphate buffer pH 7.0, 50 ug per ml of tryptophan, methionine and lysine and Cm (5 ug/ml) for 8 hours at 37°C [10X Castenholz basal stock contains per liter of distilled water nitriloacetic acid lg;
  • the pH of the medium was checked and maintained around pH 7.0 by the addition of sodium hydroxide.
  • the bacteria were harvested after 8 hours and the growth medium was separated from the bacteria by centrifugation at 6,000 g for 20 min at 4°C in the presence of protease inhibitor (2 mM phenyl methyl sulfonyl fluoride).
  • ammonium sulfate was added to 70% to the supernatant and left stirring at 4°C overnight.
  • streptavidin was collected by centrifugation at 6,000 g for 30 min and dissolved in 7 ml of 0.05M sodium
  • Iminobiotin agarose (Sigma) was prepared prior to sample loading by washing with 0.05M sodium bicarbonate buffer pH 11 + 0.5 M NaCl. After sample loading, the column was washed with 10 ml of 0.05 M sodium bicarbonate buffer pH 11 + 0.5 M NaCl and fractions were collected. The column was then eluted with 4 ml of 0.05 M ammonium acetate elution buffer pH 4.0 and fractions were collected. Absorbance at 280 nm was measured for the various fractions as shown in Figure 4. The peak fraction after the pH shift on the iminobiotin column was subjected to gel
  • B. subtilis strain BE1510 containing pBE659 was grown in synthetic S7 medium and Sav was isolated using the above method or a batch method in which the
  • the promoter and signal peptide coding region of npr gene was amplified from plasmid pBE80 (24) using primers VN16 5'-ATGCATGGTACCGATCTAACATTTTCCCC-3' (SEQ ID NO:1) and VN47 5'-GACGTATATGATATCCGCGCTAGCACCCGGCAGACTGAT-3'
  • Plasmid ⁇ BE592 was the source of the vector containing E. coli alkaline
  • phosphatase and is similar to plasmid pBE597 (24) except that it contains a seven amino acid deletion in the signal peptide.
  • E coli alkaline phosphatase. activity is indicative of export of the protein and colonies that secrete phosphatase appear blue on indicator plates (LB agar + 5 bromo-4-chloro-3-indolyl phosphate) (23).
  • E. coli strain containing plasmid pBE592 is white on LB agar + 5 bromo-4-chloro-3-indolyl phosphate because phosphatase is not secreted.
  • the PCR amplified pBE80 fragment (Kpn-EcoRV) was ligated to pBE592 digested with Kpn-EcoRV and E. coll was transformed with the ligated DNA and plated on a LB plate + 100 ug/ml ampicillln + 50 ug/ml 5 bromo-4-chloro-3-indolyl phosphate (Sigma). Blue colonies were isolated, verified by restriction analysis, and one such plasmid was designated by pBE93.
  • Oligonucleotide VN44 (GTC TCG GCC GCC GAG GCT AGC GCC GCC GGC ATC ACC GGD) (SEQ ID NO: 3) codes for a Nhe 1 site which precedes codon 15 of Sav. VN51 (GAC ACC TTC ACC AAG GTG TAG GT C GAC. AAG CCG TCC GCC) (SEQ ID NO: 4) codes for a
  • pBE670 contained the newly engineered Nhe 1 site; however, Sal I digestion resulted in a partial digestion
  • Plasmid pBE93 was digested with Nhe and Pst and ligated to Nhe 1-Pst digested pBE670, and E. coli was then transformed and screened for streptavidin
  • plasmid pBE673 One of the positive clones was designated as plasmid pBE673. Restriction analysis of pBE673 revealed that it did not contain the Sal site at the 3' end and thus it encoded for a Sav protein consisting of residues 15 to 159.
  • B. subtilis BE1500 was transformed with pBE673 and Kan R
  • BE1500(pBE673) and BE1510(pBE659) were grown in medium A + kanamycin (10 ug/ml) or chloramphenicol (5 ug/ml).
  • the extracellular streptavidin was analyzed by Western blot analysis ( Figure 5b).
  • the mobility of streptavidin produced by pBE673 was faster than that of pBE659 due to the deletion of residues 1 to 14 of mature streptavidin.
  • B. subtilis strain containing pBE673 was able to secrete streptavidin efficiently into the growth medium
  • Vectors to Make C-terminal Fusions This example describes the construction of a set of vectors that can be used to make a variety of C-terminal fusions.
  • the rationale for the construction of these vectors is at least two-fold. Firstly, the role of the C-terminal tail in the oligomerization of streptavidin in the growth medium can be studied. Secondly, one can identify the most stable bifunctional molecule that can maintain both the biotin binding feature of the Sav and contain an additional enzymatic activity such as levansucrase, alkaline phosphatase, ⁇ -lactamase, protein A and luciferase. Fusion proteins are normally rapidly clipped at the fusion junction in the
  • the restriction enzyme site that was engineered was Msc 1 because it generates a blunt end and is unique in the vectors.
  • Msc 1 site was created by a six base
  • TGG CCA TGG CCA
  • Plasmids with the Msc 1 site were identified by
  • VN62 restriction analysis
  • VN66 PBE627
  • VN67 pBE628
  • VN68 pBE629
  • This example describes the construction of a hybrid fusion protein containing streptavidin and levansucrase using a different signal peptide.
  • Single stranded DNA from plasmid pBE651 ( Figure 1a) was used to create an EcoRV site between codons 159 and the translational terminator of sav resulting in plasmid pBE653.
  • the sav gene can be isolated as an EcoRV fragment from plasmid pBE653.
  • Plasmid pBE311 codes for levansucrase and contains an EcoRV site between the second and third codon of mature levansucrase (24).
  • Plasmid pBE311 was digested with EcoRV and ligated to the EcoRV digested pBE653. In order to identify clones coding for the fusion protein, B. subtilis transformants were screened by colony immunoassay using anti-streptavidin antiserum. pBE653 contains sav gene but sav is not expressed.
  • pBE311 does not contain sav gene and therefore only the recombinants will express the fusion protein. Plasmids containing the sav fragment fused to levanscurase were designated as pBE655. B. subtilis strains containing pBE655 were grown and labelled with 35 S-methionine and the medium was analyzed by gel electrophoresis for the presence of streptavidin and levansucrase. Upon
  • transformants from pBE655A and pBE655B were found to be 39% and 86% higher, respectively, than those of pBE311.
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • xi SEQUENCE DESCRIPTION: SEQ ID NO:3:
  • MOLECULE TYPE DNA (genomic)
  • xi SEQUENCE DESCRIPTION: SEQ ID NO: 4:
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention se rapporte à un procédé pour produire de la streptavidine et des protéines de fusion de streptavidine biologiquement actives, en clonant le gène sav provenant de Streptomyces avidinii en Bacillus subtilis et en purifiant les protéines de streptavidine sécrétées prélevées du milieu de culture.
PCT/US1993/005240 1992-05-29 1993-05-27 PRODUCTION DE STREPTAVIDINE A PARTIR DU $i(BACILLUS SUBTILIS) WO1993024631A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP93914323A EP0644938A1 (fr) 1992-05-29 1993-05-27 PRODUCTION DE STREPTAVIDINE A PARTIR DU $i(BACILLUS SUBTILIS)
JP6500855A JPH07507449A (ja) 1992-05-29 1993-05-27 バチルススブチリス（Ｂａｃｉｌｌｕｓｓｕｂｔｉｌｉｓ）からのストレプトアビジンの産生

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89152492A 1992-05-29 1992-05-29
US07/891,524 1992-05-29

Publications (1)

Publication Number Publication Date
WO1993024631A1 true WO1993024631A1 (fr) 1993-12-09

Family

ID=25398345

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/005240 WO1993024631A1 (fr) 1992-05-29 1993-05-27 PRODUCTION DE STREPTAVIDINE A PARTIR DU $i(BACILLUS SUBTILIS)

Country Status (4)

Country Link
EP (1) EP0644938A1 (fr)
JP (1) JPH07507449A (fr)
CA (1) CA2136178A1 (fr)
WO (1) WO1993024631A1 (fr)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000075333A1 (fr) * 1999-06-07 2000-12-14 Neorx Corporation Fusions de genes exprimees par la streptavidine et methodes pour les utiliser
WO2005014650A2 (fr) 2003-06-16 2005-02-17 Celltech R & D, Inc. Anticorps specifiques de la sclerostine et methodes permettant d'accroitre la mineralisation osseuse
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
US7309482B2 (en) 2003-09-08 2007-12-18 E.I. Du Pont De Nemours And Company Long lasting waterproof sunscreen comprising metal oxide and peptide conditioner
US7358071B2 (en) 2004-08-16 2008-04-15 E.I. Du Pont De Nemours And Company Production of 3-hydroxycarboxylic acid using nitrilase mutants
US7445917B2 (en) 2004-12-22 2008-11-04 E.I. Du Pont De Nemours And Company Process for producing glycolic acid from formaldehyde and hydrogen cyanide
EP2016934A1 (fr) 2004-09-07 2009-01-21 E. I. Du Pont de Nemours and Company Réactifs de surface d'un corps à base de peptide pour soin personnel
WO2010080418A1 (fr) 2008-12-18 2010-07-15 E. I. Du Pont De Nemours And Company Peptides se liant à l'oxyde de fer
WO2010080419A1 (fr) 2008-12-18 2010-07-15 E. I. Du Pont De Nemours And Company Peptides qui se lient à des particules revêtues de silice
WO2010114638A1 (fr) 2009-03-30 2010-10-07 E. I. Du Pont De Nemours And Company Réactifs à base de peptides pour blanchissement des dents
US7863027B2 (en) 2007-10-31 2011-01-04 E.I. Du Pont De Nemours And Company Process for enzymatically converting glycolonitrile to glycolic acid
EP2275816A2 (fr) 2006-03-22 2011-01-19 Viral Logic Systems Technology Corp. Procédés d'identification de polypeptides cibles et utilisations dans le traitement de maladies immunologiques
WO2011051806A2 (fr) 2009-10-26 2011-05-05 Riaan Den Haan Expression hétérologue de gènes fongiques de la cellobiohydrolase 2 présents dans la levure
EP2322933A1 (fr) 2001-08-29 2011-05-18 Pacific Northwest Research Institute Diagnostic de carcinomes
EP2338906A1 (fr) 2003-06-16 2011-06-29 UCB Manufacturing, Inc. Compositions et méthodes pour l'augmentation de la mineralisation des os
EP2374465A1 (fr) 2003-09-08 2011-10-12 E. I. du Pont de Nemours and Company Conditionneurs et colorants à base de peptides pour les cheveux, la peau et les ongles
EP2441845A1 (fr) 2005-09-29 2012-04-18 Butamax (TM) Advanced Biofuels LLC Production fermentescible d'alcools à quatre carbones
EP2540817A1 (fr) 2007-05-02 2013-01-02 Butamax (TM) Advanced Biofuels LLC Procédé et cellules hôtes microbiennes pour la production d'isobutanol
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
WO2014151805A2 (fr) 2013-03-15 2014-09-25 Mascoma Corporation Expression de bêta-glucosidases pour l'hydrolyse de la lignocellulose et oligomères associés
US9365842B2 (en) 2008-05-11 2016-06-14 Stellenbosch University Nucleic acids encoding fungal cellobiohydrolases for expression in yeast
EP3301182A1 (fr) 2005-10-26 2018-04-04 Butamax (TM) Advanced Biofuels LLC Production fermentative d'alcools à quatre carbones

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3947671A1 (fr) * 2019-04-02 2022-02-09 Eli Lilly and Company Procédés de sélection et de détection de peptides de liaison

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987005026A1 (fr) * 1986-02-24 1987-08-27 The Trustees Of Columbia University In The City Of Adn codant la streptavidine, spreptavidine ainsi produite, polypeptides fusionnes comprenant des sequences d'acides amines presents dans la streptavidine et leurs utilisations
WO1991000913A1 (fr) * 1989-07-07 1991-01-24 E.I. Du Pont De Nemours And Company Vecteurs d'expression d'induction
WO1992003560A1 (fr) * 1990-08-28 1992-03-05 E.I. Du Pont De Nemours And Company Procede de selection rapide de vecteurs de secretion efficaces

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987005026A1 (fr) * 1986-02-24 1987-08-27 The Trustees Of Columbia University In The City Of Adn codant la streptavidine, spreptavidine ainsi produite, polypeptides fusionnes comprenant des sequences d'acides amines presents dans la streptavidine et leurs utilisations
WO1991000913A1 (fr) * 1989-07-07 1991-01-24 E.I. Du Pont De Nemours And Company Vecteurs d'expression d'induction
WO1992003560A1 (fr) * 1990-08-28 1992-03-05 E.I. Du Pont De Nemours And Company Procede de selection rapide de vecteurs de secretion efficaces

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
WO2000075333A1 (fr) * 1999-06-07 2000-12-14 Neorx Corporation Fusions de genes exprimees par la streptavidine et methodes pour les utiliser
EP2913673A1 (fr) 2001-08-29 2015-09-02 Pacific Northwest Research Institute Diagnostic du carcinome de l'ovaire
EP2322933A1 (fr) 2001-08-29 2011-05-18 Pacific Northwest Research Institute Diagnostic de carcinomes
WO2005014650A2 (fr) 2003-06-16 2005-02-17 Celltech R & D, Inc. Anticorps specifiques de la sclerostine et methodes permettant d'accroitre la mineralisation osseuse
EP2338906A1 (fr) 2003-06-16 2011-06-29 UCB Manufacturing, Inc. Compositions et méthodes pour l'augmentation de la mineralisation des os
EP2341071A1 (fr) 2003-06-16 2011-07-06 UCB Manufacturing, Inc. Compositions et méthodes pour l'augmentation de la minéralisation des os
US7309482B2 (en) 2003-09-08 2007-12-18 E.I. Du Pont De Nemours And Company Long lasting waterproof sunscreen comprising metal oxide and peptide conditioner
EP2374465A1 (fr) 2003-09-08 2011-10-12 E. I. du Pont de Nemours and Company Conditionneurs et colorants à base de peptides pour les cheveux, la peau et les ongles
US7358071B2 (en) 2004-08-16 2008-04-15 E.I. Du Pont De Nemours And Company Production of 3-hydroxycarboxylic acid using nitrilase mutants
EP2016934A1 (fr) 2004-09-07 2009-01-21 E. I. Du Pont de Nemours and Company Réactifs de surface d'un corps à base de peptide pour soin personnel
US8008052B2 (en) 2004-12-22 2011-08-30 E.I. Du Pont De Nemours And Company Process for producing glycolic acid from formaldehyde and hydrogen cyanide
US7939303B2 (en) 2004-12-22 2011-05-10 E. I. Du Pont De Nemours And Company Process for producing glycolic acid from formaldehyde and hydrogen cyanide
US7445917B2 (en) 2004-12-22 2008-11-04 E.I. Du Pont De Nemours And Company Process for producing glycolic acid from formaldehyde and hydrogen cyanide
US8110382B2 (en) 2004-12-22 2012-02-07 E. I. Du Pont De Nemours And Company Process for producing glycolic acid from formaldehyde and hydrogen cyanide
US7732172B2 (en) 2004-12-22 2010-06-08 E. I. Du Pont De Nemours And Company Process for producing glycolic acid from formaldehyde and hydrogen cyanide
US8084238B2 (en) 2004-12-22 2011-12-27 E. I. Du Pont De Nemours And Company Process for producing glycolic acid from formaldehyde and hydrogen cyanide
US8071343B2 (en) 2004-12-22 2011-12-06 E. I. Du Pont De Nemours And Company Process for producing glycolic acid from formaldehyde and hydrogen cyanide
US7741083B2 (en) 2004-12-22 2010-06-22 E. I. Du Pont De Nemours And Company Process for producing glycolic acid from formaldehyde and hydrogen cyanide
EP2441845A1 (fr) 2005-09-29 2012-04-18 Butamax (TM) Advanced Biofuels LLC Production fermentescible d'alcools à quatre carbones
EP3301182A1 (fr) 2005-10-26 2018-04-04 Butamax (TM) Advanced Biofuels LLC Production fermentative d'alcools à quatre carbones
US8293500B2 (en) 2006-03-22 2012-10-23 Viral Logic Systems Technology Corp. Methods for identifying polypeptide targets and uses thereof for treating immunological diseases
EP2275816A2 (fr) 2006-03-22 2011-01-19 Viral Logic Systems Technology Corp. Procédés d'identification de polypeptides cibles et utilisations dans le traitement de maladies immunologiques
EP2322931A2 (fr) 2006-03-22 2011-05-18 Viral Logic Systems Technology Corp. Procédés d'identification de polypeptides cibles et utilisations dans le traitement de maladies immunologiques
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
EP2540817A1 (fr) 2007-05-02 2013-01-02 Butamax (TM) Advanced Biofuels LLC Procédé et cellules hôtes microbiennes pour la production d'isobutanol
US7863027B2 (en) 2007-10-31 2011-01-04 E.I. Du Pont De Nemours And Company Process for enzymatically converting glycolonitrile to glycolic acid
US7867737B2 (en) 2007-10-31 2011-01-11 E.I. Du Pont De Nemours And Company Process for enzymatically converting glycolonitrile to glycolic acid
US7927846B2 (en) 2007-10-31 2011-04-19 E. I. Du Pont De Nemours And Company Process for enzymatically converting glycolonitrile to glycolic acid
US7927847B2 (en) 2007-10-31 2011-04-19 E. I. Du Pont De Nemours And Company Process for enzymatically converting glycolonitrile to glycolic acid
US7919288B2 (en) 2007-10-31 2011-04-05 E. I. Du Pont De Nemours And Company Process for enzymatically converting glycolonitrile to glycolic acid
US7919286B2 (en) 2007-10-31 2011-04-05 E. I. Du Pont De Nemours And Company Process for enzymatically converting glycolonitrile to glycolic acid
US7919287B2 (en) 2007-10-31 2011-04-05 E.I. Du Pont De Nemours And Company Process for enzymatically converting glycolonitrile to glycolic acid
US7875443B2 (en) 2007-10-31 2011-01-25 E.I. Du Pont De Nemours And Company Process for enzymatically converting glycolonitrile to glycolic acid
US7871802B2 (en) 2007-10-31 2011-01-18 E.I. Du Pont De Nemours And Company Process for enzymatically converting glycolonitrile to glycolic acid
US7867738B2 (en) 2007-10-31 2011-01-11 E.I. Du Pont De Nemours And Company Process for enzymatically converting glycolonitrile to glycolic acid
US7867739B2 (en) 2007-10-31 2011-01-11 E. I. Du Pont De Nemours And Company Process for enzymatically converting glycolonitrile to glycolic acid
US9365842B2 (en) 2008-05-11 2016-06-14 Stellenbosch University Nucleic acids encoding fungal cellobiohydrolases for expression in yeast
US11530428B2 (en) 2008-05-11 2022-12-20 Stellenbosch University Nucleic acids encoding fungal cellobiohydrolases for expression in yeast
WO2010080419A1 (fr) 2008-12-18 2010-07-15 E. I. Du Pont De Nemours And Company Peptides qui se lient à des particules revêtues de silice
WO2010080418A1 (fr) 2008-12-18 2010-07-15 E. I. Du Pont De Nemours And Company Peptides se liant à l'oxyde de fer
WO2010114638A1 (fr) 2009-03-30 2010-10-07 E. I. Du Pont De Nemours And Company Réactifs à base de peptides pour blanchissement des dents
WO2011051806A2 (fr) 2009-10-26 2011-05-05 Riaan Den Haan Expression hétérologue de gènes fongiques de la cellobiohydrolase 2 présents dans la levure
US9447398B2 (en) 2009-10-26 2016-09-20 Stellenbosch University Heterologous expression of fungal cellobiohydrolase 2 genes in yeast
US10196622B2 (en) 2009-10-26 2019-02-05 Stellenbosch University Heterologous expression of fungal cellobiohydrolase 2 genes in yeast
WO2014151805A2 (fr) 2013-03-15 2014-09-25 Mascoma Corporation Expression de bêta-glucosidases pour l'hydrolyse de la lignocellulose et oligomères associés
US10612061B2 (en) 2013-03-15 2020-04-07 Lallemand Hungary Liquidity Management Llc Expression of beta-glucosidases for hydrolysis of lignocellulose and associated oligomers
US11168315B2 (en) 2013-03-15 2021-11-09 Lallemand Hungary Liquidity Management Llc Expression of beta-glucosidases for hydrolysis of lignocellulose and associated oligomers

Also Published As

Publication number Publication date
JPH07507449A (ja) 1995-08-24
EP0644938A1 (fr) 1995-03-29
CA2136178A1 (fr) 1993-12-09

Similar Documents

Publication Publication Date Title
WO1993024631A1 (fr) PRODUCTION DE STREPTAVIDINE A PARTIR DU $i(BACILLUS SUBTILIS)
US5736131A (en) Hybrid toxin
Nagahari et al. Secretion into the culture medium of a foreign gene product from Escherichia coli: use of the ompF gene for secretion of human beta‐endorphin.
US4977247A (en) Immobilized protein G variants and the use thereof
CA2122135C (fr) Streptavidine recombinante
EP0196864A2 (fr) Scission et sécrétion des protéines recombinantes à l'aide du système de la phosphatase alcaline, séquences de l'ADN à utiliser dans ce système et cellules transformées au moyen de ces séquences
EP0750634A1 (fr) Secretion amelioree de polypeptides
US5885811A (en) Leader sequence inducing a post-translational modification of polypeptides in bacteria gene therefor and subtilin variant of enhanced stability and activity
NO309200B1 (no) Genledersekvens som induserer en post-translasjonell modifikasjon av polypeptider i bakterier og polypeptidsekvens
US4711843A (en) Method and vector organism for controlled accumulation of cloned heterologous gene products in Bacillus subtilis
Betton et al. In vivo assembly of active maltose binding protein from independently exported protein fragments.
Holland et al. [11] Secretion of heterologous proteins in Escherichia coli
EP0546049B1 (fr) Procede de selection rapide de vecteurs de secretion efficaces
US6780408B1 (en) Genes encoding hybrid bacillus thuringiensis toxins
EP0543195B1 (fr) Procédé biosynthétique pour la préparation de protéines
EP0483224B1 (fr) Vecteurs d'expression d'induction
Maclntyre et al. Requirement of the SecB chaperone for export of a non-secretory polypeptide in Escherichia coli
DK175020B1 (da) Fremgangsåde til udtrykkelse og ekstracellulær udskillelse af proteiner i G(-)bakterie, rekombinant DNA-konstruktion og plasmidvektor kodende herfor, samt G(-)bakterie indeholdende disse
US5171673A (en) Expression of heterologous dna using the bacillus coagulans amylase gene
JP4271396B2 (ja) 乳酸菌中の分泌シグナルを分離する方法及びラクトコッカス・ラクティスから分離された新規な分泌シグナル
US5843709A (en) Biosynthetic process for the preparation of chemical compounds
US5212083A (en) Sequence for stabilizing proteins in bacteria
CA1338338C (fr) Methode de preparation de proteines etrangeres dans les streptomycetes
EP0342658B1 (fr) Procédé biosynthétique de préparation de produits chimiques
US7223742B2 (en) Enhanced solubility of recombinant proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1993914323

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2136178

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1993914323

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1993914323

Country of ref document: EP